Targeted Antibody Provides Significant Relief From Itchy Nodular Condition

(MedPage Today) -- BOSTON -- In the first-ever phase III trial for prurigo nodularis, dupilumab (Dupixent) significantly reduced itching after as little as 12 weeks of treatment.
The results showed that 37.2% of patients in the dupilumab arm...

Source: MedPage Today Dermatology - March 28, 2022 Category: Dermatology Source Type: news